| About the author: |
R. V. Baryliak, D. Z. Vorobets, O. V. Melnyk, R. V. Fafula, Z. D. Vorobets |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The purpose of the present work was to study the enzyme activity and kinetic properties of NO-synthase in blood lymphocytes of women with ovarian cancer. Studies were conducted on the blood lymphocytes of women with ovarian cancer of the II-ІV degrees (n=26) and healthy women (n=24, control group). It has been found that constitutive isoform of NO-synthase of blood lymphocytes of women with ovarian cancer was 4.0 fold lower compared to control group. The activity of inducible NO-synthase in blood lymphocytes of practically healthy women was (1.52±0.46) nmol NADPH(H+)/min∙mg of protein and in women with ovarian cancer it increased in 144 times. The maximum rate of constitutive isoform of NO-synthase reaction in patients with ovarian cancer was reduced 5 fold and for inducible NO-synthase reaction was increased in tens of times compared to control group. For oncopathology the imaginary affinity constant to arginine for inducible NO-synthase was in 5.4 times lower compared to inducible NO-synthase of control group. The inhibition of constitutive isoform of NO-synthase occurs by competitive type – by reducing the rate of enzyme reaction. |
| Tags |
ovarian cancer, lymphocytes, Nitrogen (II) oxide, NO-synthase, arginase |
| Bibliography |
- Bryan NS. Nitric oxide enhancement strategies. Future Sci. 2015; 1(1):48–53. doi: 10.4155/FSO.15.48
- Calcerrada P, Peluffo G, Radi R. Nitric oxide-derived oxidants with a focus on peroxynitrite: molecular targets, cellular responses and therapeutic implications. Curr. Pharm. Des. 2011; 17(35):3905–32. doi: 10.2174/138161211798357719.
- El-Sehemy A, Postovit LM, Fu Y. Nitric oxide signaling in human ovarian cancer: a potential therapeutic target. Nitric Oxide. 2016;54:30–7. doi: 10.1016/j.niox.2016.02.002.
- Forsterman U, Sessa WC. Nitric Oxide synthases: regulation and function. Eur. Heart J. 2012; 33(7):829–37. doi: 10.1093/eurheartj/ehr304.
- Hrabarova E, Juranek I, Soltes L. Pro-oxidative effect of peroxynitrite regarding biological systems: a special focus on high-molar-mass hyaluronan degradation. Gen. Physiol. Biophys. 2011;30(3):223–38. doi: 10.4149/gpb_2011_03_223.
- Kielbik M, Szulc I, Brzezinska M, Bednarska K, Przygodzka P, Solowska Z, et al. Nitric oxide donors reduce the invasion ability of ovarian cancer sells in vitro. Anticancer Drugs. 2014; 25(10):1141–51. DOI:10.1007/978-1-4419-1432-3_24
- Lu C, Zhou L, Ouyang J, Huajing MM. Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer. Medicine. 2019;98(24):58–76. doi: 10.1097/MD.0000000000015876
- Maleki J, Nourbahsh M, Shabani M, Korani M, Nourazarian SM, Dahaghi M, Maghadasi M. 17ß-Estradil stimulates generation of reactive species oxygen and reactive oxide in ovarian adenocarcinoma cells (OVCAR 3). Intern. J. Cancer Management. 2015; 8(3):23–32. doi: 10.17795/ijcp2332
- Siddique YH, Ara G, Afzal M. Estimation of lipid peroxidation induced by hydrogen peroxide in cultured human lymphocytes. Dose Response. 2012; 10(1):1–10. doi: 10.2203/dose-response.10-002.Siddique.
- Somasundaram V, Nadhal R, Hemalatha SR, SengodanSK, Srinivas P. Nitric oxide and reactive oxygen species: clues to target oxidative damage repair defective breast cancer. Critical Rev. Oncology/Hematology. 2016;101:184–92. doi: 10.1016/j.critrevonc.2016.03.004.
- Vannini F, Kashfi K, Nath N. The dual role of iNOS in cancer. Redox Biol. 2015; 6:334–43. doi: 10.1016/j.redox.2015.08.009.
- Yakubets OI, Fafula RV, Vorobets DZ, Vorobets ZD. Peculiarities of arginase and NO-synthase pathways of L-arginine metabolism in peripheral blood lymphocytes of patients with ovarian cancer. Ukr Biochem J. 2013; 85(5):105–113. doi: http://dx.doi.org/10.15407/ubj85.05.105.
|
| Publication of the article |
«World of Medicine and Biology» №3(77), 2021 year, 028-033 pages, index UDK 612.015.33.+616.153.94 |
| DOI |
10.26724/2079-8334-2021-3-77-28-33 |
